Hence, therapeutic upregulation of IRF8 can reduce persistent LSCs during treatment of CML with BCRABL-targeted tyrosine kinase inhibitors (TKIs) (64). Here, IRF8 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.